A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Fenebrutinib (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 05 Jun 2018 Planned End Date changed from 22 Feb 2019 to 23 Jan 2019.
    • 05 Jun 2018 Planned primary completion date changed from 25 Jan 2019 to 23 Jan 2019.
    • 05 Mar 2018 Planned End Date changed from 10 Apr 2018 to 22 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top